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Abstract: Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s 
sarcoma (KS), one of the most prevalent cancers of people living with HIV/AIDS in sub-Saharan 
Africa. The seroprevalence for KSHV is high in the region, and no prophylactic vaccine against the 
virus is available. In this study, we characterized the antigenic targets of KSHV-specific 
neutralizing antibodies (nAbs) in asymptomatic KSHV-infected individuals and KS patients with 
high nAbs titers. We quantified the extent to which various KSHV envelope glycoproteins (gB, 
ORF28, ORF68, gH, gL, gM, gN and gpK8.1) adsorbed/removed KSHV-specific nAbs from the 
plasma of infected individuals. Our study revealed that plasma from a majority of KSHV 
neutralizers recognizes multiple viral glycoproteins. Moreover, the breadth of nAbs responses 
against these viral glycoproteins varies among endemic KS, epidemic KS and asymptomatic 
KSHV-infected individuals. Importantly, among the KSHV glycoproteins, the gH/gL complex, but 
neither gH nor gL alone, showed the highest adsorption of KSHV-specific nAbs. This activity was 
detected in 80% of the KSHV-infected individuals regardless of their KS status. The findings 
suggest that the gH/gL complex is the predominant antigenic determinant of KSHV-specific nAbs. 
Therefore, gH/gL is a potential target for development of KSHV prophylactic vaccines. 
Keywords: KSHV; KS; glycoproteins; gH; gL; neutralizing antibodies 
 
1. Introduction 
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8 
(HHV-8), is the causative agent of all forms of Kaposi sarcoma (KS) and two additional 
lymphoproliferative diseases, primary effusion lymphoma (PEL) and multicentric Castleman’s 
disease (MCD) [1,2]. The distribution of KSHV varies globally. In some areas such as sub-Saharan 
Africa (SSA), KSHV seroprevalence can be as high as 80%, whereas in the US and Europe, the 
prevalence is 3%–20% [3,4]. The prevalence of KS increases significantly with HIV-1 infection, 
making it one of the leading cancers among people living with HIV/AIDS in SSA [5,6]. Globally, it is 
estimated that nearly 44,000 new cases of KS emerge annually, with the highest incidence occurring 
in Africa, where KSHV is endemic [7]. The two main clinical manifestations of KS are Endemic KS 
(EnKS) and Epidemic KS (EpKS). EnKS is found among HIV-1 negative individuals, whereas EpKS 
is associated with HIV-1 co-infection [8,9]. Additionally, in specific ethnic groups of elderly men of 
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Mediterranean or Eastern European descent, there exists Classical KS (CKS), and Iatrogenic KS (IKS) 
is associated with drug-induced immune suppression [10]. The recurrence rate for KS is high even 
with chemo- or radiotherapy [11]. Therefore, the most cost-effective strategy to reduce KS incidence 
is to prevent KSHV infection through vaccination, and understanding the antigenic determinant of 
KSHV-specific nAbs will contribute to informative vaccine research for KSHV. 
Although KSHV-specific nAbs have been reported in KS patients and KSHV-infected 
individuals, their role in KSHV pathogenesis is not known [12,13]. More importantly, it is unclear 
whether having KSHV-specific nAbs prior to exposure to KSHV could be beneficial in preventing its 
infection and therefore could serve as an adaptive correlate of protection against KS development. 
Based on lessons learned from vaccination against other viruses, such as influenza, nAbs elicited 
through vaccination primarily target viral membrane surface proteins [14,15]. It has also been shown 
that immunization with KSHV envelope glycoproteins gB, gpK8.1 and gH/gL can elicit nAbs 
responses in animal models [16,17]. However, whether these glycoproteins are the targets for nAbs 
elicited through infection, as in KSHV-infected individuals, and whether these glycoproteins can 
induce nAbs in immunized humans, remain to be determined. 
Herpesviruses initiate infection via binding to various receptors on the surface of target cells. 
This process is primarily mediated by multiple viral glycoproteins embedded in the viral envelope 
[18]. These glycoproteins play important roles in virus attachment to target cells and fusion of the 
viral envelope with either cytoplasmic or endosomal membranes, as well as the virion 
morphogenesis and egress [19]. KSHV incorporates eight glycoproteins into its virion envelope: 
ORF8 (gB), ORF28, ORF68, ORF22 (gH), ORF47 (gL), ORF39 (gM), ORF53 (gN) and gpK8.1 [20]. 
Studies have shown that distinct envelope glycoproteins are involved in KSHV infection of different 
cell types, with gpK8.1, gB, and gH/gL as the major players [21–23]. The current model for KSHV 
infection of most cell types suggests that virion binding is mainly initiated via gB or gpK8.1 
interactions with the host cell heparin sulfate (HS) or integrin proteins, which then trigger gH/gL 
engagement with the ephrin receptor tyrosine kinases leading to fusion [24–30]. Given the critical 
roles of KSHV glycoproteins in viral entry, we hypothesized that KSHV glycoproteins could play a 
pivotal role in the elicitation of KSHV-specific nAbs in infected individuals. To test this hypothesis, 
we studied the ability of various KSHV glycoproteins in the adsorption/removal of KSHV-specific 
nAbs from the plasma of KSHV-infected individuals who have high nAbs titers. Glycoprotein 
targeted by the nAbs could be identified by a reduction in the nAbs response after depletion with a 
specific glycoprotein. 
With this approach, we have characterized the variable specificity of nAb responses and 
demonstrated that multiple KSHV glycoproteins are the targets of KSHV-specific nAbs in 
KSHV-infected individuals regardless of their KS status. The results reveal that the gH/gL complex 
depleted the highest amount of KSHV-specific nAbs in the majority of KSHV-infected individuals, 
suggesting that gH/gL is the most prominent target of KSHV-specific nAbs, and therefore the most 
plausible antigenic target for prophylactic vaccine development against KSHV. 
2. Materials and Methods 
2.1. Ethics Statement 
Written informed consent was obtained from all study participants from Tanzania and Zambia 
for sample collection and testing. The study was conducted in accordance with the Declaration of 
Helsinki and approved by the review boards of Tanzania National Institute for Medical Research, 
Ocean Road Cancer Institute, University of Zambia Biomedical Research Ethics Committee and the 
University of Nebraska-Lincoln (Tanzania CRITIC: IRB Number: 20141014709FB, 10/25/2019 and 
Zambia ZAMDAPP: IRB Number: 20170817442FB, 08/09/2019). 
2.2. Cell Cultures 
Human embryonic kidney T (293T) and BC-3 cells were obtained from ATCC (CRL-3217 and 
CRL-2277, respectively). 293T cells were maintained in Dulbecco’s modified Eagle medium (DMEM) 
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with 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin (P/S). BC-3 cells were maintained 
in RPMI with 20% FBS and 1% P/S. Vero.219 cells (a gift from Jeffrey Vieira [31]) were maintained in 
DMEM with 10% FBS and 1% P/S and 6 µg/mL of puromycin. All cell cultures were maintained at 
37 °C in a 5% CO2 incubator. 
2.3. KSHV Serological Assays 
The KSHV serostatus and total anti-KSHV antibody titers were determined by 
immunofluorescence assay (IFA) on activated BC-3 cells as previously described [32]. To determine 
the total KSHV-specific nAbs titer, neutralization assays were carried out in triplicate as previously 
described [13]. Briefly, heat-inactivated plasma (56 °C for 1 h) from study participants was incubated 
with rKSHV.219 virus at 1:50 dilution at 37 °C for 1 h. 293T cells seeded in 96-well plates (2.5 × 104 
cells/well) were infected with the virus–plasma mixture, centrifuged (400× g for 20 min) and then 
incubated for 72 hours at 37 °C. Neutralization activity of the plasma, relative to a KSHV negative 
plasma, was then quantified by flow cytometry at 72 hours postinfection as follows: 
%neutralization = 100 – [(s/c) × 100] (1) 
S = % GFP positive cells in wells with KSHV positive plasma. 
C = % GFP positive cells in wells with KSHV negative plasma. 
Plasma samples that were positive for KSHV nAbs at the 1:50 dilution were further titrated by 
2-fold dilutions from 1:50 to 1:3200 to define the IC50 (50% inhibitory concentration). 
2.4. HIV-1 Serology and Plasma Viral Load Quantification by Real-Time PCR 
The HIV-1 diagnosis was made according to Alere Determine HIV-1/2 Ag/Ab Combo test in 
Zambia and Tanzania HIV Rapid Test Algorithm. The HIV-1 serology results were verified using 
HIV-1–2.0 First Response kit (Premier Medical Corporation Ltd., Mumbai, India). To quantify HIV-1 
plasma viral load, the viral RNA was extracted from plasma following the QIAamp viral RNA 
extraction protocol (Qiagen, Hilden, Germany) and measured using the RNA Ultra-Sense One-Step 
quantitative real-time PCR (qPCR) system (Applied Biosystems, Foster City, CA, USA) as previously 
published [33]. 
2.5. KSHV Virion in Plasma 
Plasma of study participants (400 µL) was centrifuged at 8000× g at room temperature for 10 
min to remove residual cells. Then, 15 µL of DNase-I (Qiagen, Hilden, Germany) was added to each 
sample and incubated for 2 hours at room temperature to digest cell-free genomic DNA. The 
samples were then incubated at 65 °C for 20 min to inactivate DNase-I, and viral DNA was extracted 
by the QIAamp DNA mini kit according to the manufacturer’s protocol (Qiagen, Hilden, Germany). 
The presence of KSHV virion in plasma was then determined by nested PCR of the extracted viral 
DNA using primers for the open reading frame 26 (ORF26) amplicon (forward 
5′-AGCCGAAAGATTCCACCAT-3′ and reverse 5′-TCCGTGTTGTCTACGTCCAG-3′ in the first 
round and forward 5′-CGAATCCAACGGATTTGACCTC-3′ and reverse 
5′-CCCATAAATGACACATTGGTGGTA-3′ in the second round reaction) under conditions 
previously described [34]. Contamination of the extracted viral DNA by cell-free genomic DNA was 
ruled out through a negative PCR result for the human β-actin gene. 
2.6. KSHV Envelope Glycoprotein Constructs 
To construct the KSHV gB, gpK8.1, gH/gL, gM, gN, ORF28 and ORF68 3XFLAG-tagged 
plasmids, the full-length open reading frame sequence of each individual glycoproteins (NCBI 
reference sequence #NC_009333.1) was PCR-amplified from BC-3 genomic DNA and cloned into the 
pcDNA3.1 mammalian expression vector (Invitrogen, Carlsbad, CA, USA) with a 3xFLAG fused to 
the carboxyl-terminus of each glycoprotein. The resulted plasmids were confirmed with restriction 
enzyme digestions and sequencing. 
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2.7. Immunoblot 
1 × 106/well of 293T cells were seeded into 6-well plates. At 24 hours postseeding, 2 µg of each 
KSHV glycoprotein expressing plasmids were transfected into the 293T cells using FuGENE 6 
transfection reagent (Promega, Madison, WI, USA). After 72 hours, the transfected cells were lysed 
in RIPA lysis buffer with proteinase inhibitor cocktail (Thermo Scientific, Waltham, MA, USA). The 
extracted protein was then measured by Pierce BCA protein assay (Thermo Scientific, Waltham, MA, 
USA) and an equal amount of protein from each glycoprotein transfected cell culture was loaded 
and resolved in a 4%–15% gradient SDS-PAGE (Bio-Rad, Hercules, CA, USA). The proteins were 
then transferred onto a nitrocellulose membrane and blocked with 5% skim milk in 1X PBS with 
0.5% Tween 20 for 2 hours at room temperature. The membranes were then incubated with either 
mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich, St. Louis, MO, USA) at 1:100 or mouse 
monoclonal anti-GAPDH (6C5) IgG (Santa Cruz Biotechnology, Dallas, TX, USA) at 1:2000 overnight 
at 4 °C. The next day, after washing, the membranes were incubated with donkey anti-mouse 
800CW or 680CW antibodies (Li-Cor Biosciences, Lincoln, NE, USA) at 1:10000 for 2 hours at room 
temperature and then washed repeatedly. The membranes were then visualized with Odyssey 
infrared imager (Li-Cor Biosciences, Lincoln, NE, USA). 
2.8. Immunohistochemistry (IHC) 
1 × 104/chamber of 293T cells were seeded into 4-well chamber slides. At 24 hours postseeding, 
equal copy number of KSHV glycoprotein-expressing plasmids were transfected into 293T cells 
using FuGENE 6 transfection reagent (Promega, Madison, WI, USA). After 72 hours, the slides were 
washed and fixed in 4% paraformaldehyde for 30 min at room temperature. The fixed slides were 
then incubated in 0.3% H2O2 methanol solution for 30 min at room temperature, followed by washes 
and antigen retrieved in sodium citrate solution for 15 min at 98 °C. After cooling to room 
temperature, the slides were washed and blocked with 10% normal goat serum for 30 min at room 
temperature and incubated with mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich, St. 
Louis, MO, USA) at 1:300 in blocking solution at 4 °C overnight. The next day, the slides were 
washed and incubated with Dako EnVision+ System-HRP anti-mouse polymer for 30 min at room 
temperature, and color was developed with DAB solution (Dako, Santa Clara, CA, USA). 
Counterstaining of the nucleus was performed using hematoxylin. The final stained slides were then 
air-dried and rinsed twice in xylene solution for 5 min each, and coverslip was added with Cytoseal 
60 (Thermo Scientific, Waltham, MA, USA). The slides were examined with a Nikon Eclipse 50i 
microscope under 20X magnification. Three times 3 fields of pictures (i.e., 9 pictures) were taken at 
20X magnification and digitally stitched using NIS-Elements imaging software (Nikon, Tokyo, 
Japan). 
2.9. Immunofluorescence Assay for Protein Expression 
5 × 104/chamber of 293T cells were seeded into 8-well chamber slides. At 24 hours postseeding, 
equal copy numbers of KSHV glycoprotein expressing plasmids were transfected into 293T cells 
using FuGENE 6 transfection reagent (Promega, Madison, WI, USA). After 72 hours, the slides were 
washed and fixed in 4% paraformaldehyde for 30 min at room temperature. The fixed slides were 
incubated with a heat-inactivated (56 °C for 1 h) pooled plasma from all the study subjects at 1:40 at 
4 °C overnight. The next day, the slides were washed and incubated with mouse monoclonal 
anti-human antibody (ATCC, CRL-1786) at 1:4 at 37 °C for 1 h. Then the slides were washed and 
incubated with CY2 AffiniPure donkey anti-mouse IgG (H+L) antibody (Jackson ImmunoResearch, 
West Grove, PA, USA) at 1:200 at 37 °C for 1 h. Next, the slides were washed and stained with 
0.001% Evans blue for 5 min at room temperature. After staining, the slides were washed and 
coverslip was mounted with mounting media. The slides were examined with a Nikon Eclipse 50i 
microscope under 20X magnification. 
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2.10. rKSHV.219 Production 
Vero.219 cells, a cell line latently infected with a recombinant KSHV encoding the green 
fluorescent protein, were used to generate rKSHV.219 viruses. Briefly, a total of 18 × 106 Vero.219 
cells per flask were seeded into T-225 flasks. At 24 hours postseeding, the culture medium was 
removed, and 3300 viral particles of adenovirus type 5 encoding KSHV RTA (Ad5-RTA) (gift from 
Dr. Jean Gustin) were incubated with the cells in the presence of 5M valproic acid without (w/o) 
puromycin. The next day, the cells were washed and fresh medium w/o valproic acid and 
puromycin was added. After 48 hours, the supernatant was collected and was cleared by a 10 min 
spin at 2000 rpm. Then, the supernatant was collected and concentrated through a 20% sucrose 
cushion by spinning at 28000 rpm for 2 h. The virus pellet was resuspended in medium and titered 
on 293T using flow cytometry for measuring GFP positive cells to determine the amounts of virus 
needed to achieve 40%–50% GFP positive cells in the neutralization assays (Supplementary Figure 
S1A). 
2.11. KSHV Glycoproteins Transfected 293T Cells Adsorption of nAbs from Plasma 
Thirteen µL of the heat-inactivated plasma (56 °C for 1 h) was incubated with 1 × 106 293T cells 
(transfected with equal copy number of KSHV envelope glycoprotein plasmids either individually 
or in combination) in 578 µL volumes of medium (DMEM containing 10% FBS, 1% P/S and 1% 
protease inhibitor cocktail) at 4°C overnight. The number of cells and temperature used for 
adsorption were optimized based on the gH/gL complex (Supplementary Figure 1B,C). After 
incubation with the KSHV glycoproteins expressing 293T cells, the plasma-cell mixture was spun 
down at 6000× g for 5 min to remove the cell pellets, and the supernatant was collected. Then, 
neutralization assays were performed in triplicate, the supernatant was incubated with 59 µL of 
rKSHV.219 at 37 °C for 1 h. 293T cells in 96-well plates (2.5 × 104 cells/well) were then infected with 
virus–plasma mixture, centrifuged (400× g for 20 min at room temperature) and incubated for 72 h. 
Neutralization was quantified by flow cytometry at 72 hours postinfection. The percentage of 
neutralization was defined as follows: 
%neutralizatin = 100 - [(s/c) × 100] (2) 
S = % GFP positive cells in wells with KSHV glycoproteins absorbed sample plasma. 
C = % GFP positive cells in wells with pooled plasma from HIV-1 and KSHV double-negative 
donors (n = 10). 
The percentage of relative nAbs adsorption was defined as follows: 
Relative % nAbs adsorption = [(B – N)/B] × 100 (3) 
N = % neutralization of KSHV glycoproteins absorbed sample plasma. 
B = % neutralization of sample plasma absorbed with empty-vector-transfected 293T cells. 
2.12. Statistical Analysis 
Statistical analyses were carried out using GraphPad Prism 5 (GraphPad Software Inc, San 
Diego, CA, USA). The comparison of nAbs responses to gH/gL complex with other KSHV 
glycoproteins among all the participants was performed using the Mann–Whitney test. The 
comparison of nAbs responses to each KSHV glycoprotein in the EnKS, EpKS and non-KS groups 
was performed using the Mann–Whitney test. Correlation between the extent of nAbs absorbed by 
gH/gL and total anti-KSHV and nAbs responses was performed using the nonparametric Spearman 
correlation analysis.
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3. Results 
3.1. Study Cohort 
The study cohort was comprised of 25 individuals from Zambia and Tanzania: 21 KS patients 
and 4 asymptomatic KSHV seropositive participants. Among the KS patients, there were 15 EpKS 
and 6 EnKS individuals, while the non-KS participants consisted of one HIV-1- and three HIV-1+ 
individuals (Table 1). The age of the study subjects ranged from 24 to 68 years old, with a median of 
27 years for EnKS, 41 years for EpKS and 39 years for non-KS participants. All the EnKS cases were 
male, while 73.3% of the EpKS cases were male, and all the non-KS cases were female (Table 1). The 
duration of symptomatic KS ranged from 2 months to 108 months, with a median of 12 months for 
EnKS and 24 months for EpKS. The majority of the EpKS patients were on anti-retroviral treatment 
and had HIV-1 plasma viral load below detection limits. The 1/IC50, which indicates the dilution of 
plasma that accomplish 50% inhibition of KSHV infection, was performed using neutralization 
assays to determine the KSHV-specific nAbs titers in the plasma. The KSHV serostatus and total 
anti-KSHV antibody titers for all participants were determined by immunofluorescence assay (IFA). 
Both the total anti-KSHV antibody and KSHV-specific nAbs titers were variable among 
KSHV-infected individuals. For the available samples, the presence of KSHV virions in plasma was 
analyzed by PCR for the KSHV ORF26 gene. All participants in this cohort are high neutralizers as 
defined by our flow cytometry-based neutralization assay (supplementary Figure S2). 
Table 1. Characteristics of the study cohort. 
 Patient 
ID Sex Age 
KS 
Months 
HIV-1 
Months 
HIV-1 Plasma Viral 
Load [copies/mL] 
ARV 
Months 1/IC50 IFA 
Plasma 
ORF26 
PCR 
Endemic KS 
(KSHV+, 
HIV-1−) 
3096 M 27 3 NA NA NA 395.1 20480 − 
3111 M 24 7 NA NA NA 438.9 5120 − 
3135 M 25 12 NA NA NA 1672.4 5120 − 
3137 M 51 NI NA NA NA 292.2 5120 − 
3139 M 27 14 NA NA NA 281.8 40960 + 
21182 M 57 108 NA NA NA 115.7 10240 NI 
Epidemic KS 
(KSHV+, 
HIV-1+) 
3060 F 44 8 12 BDL 9 1259.4 40960 + 
3080 F 21 3 5 BDL 1 199.9 1280 − 
3122 M 34 3 24 BDL 24 2779.9 40960 + 
21001 F 36 18 168 BDL 10 605.3 2560 + 
21009 M 36 60 120 BDL 9 232.2 1280 − 
21017 M 38 24 36 BDL 36 845.7 1280 + 
21021 M 41 60 NI 1.16 × 105 NI 1606.7 1280 + 
21028 M 30 24 24 BDL 24 1167.5 5120 − 
21052 F 37 84 NI BDL 48 1971.7 2560 − 
21053 M 44 9 5 BDL 4 890.4 2560 − 
21062 M 68 24 NI BDL NI 715.8 5120 + 
TIL002 M 68 3 48 2201 36 285.2 5120 NI 
TIL007 M 46 72 72 33 72 407.1 5120 NI 
TIL018 M 55 48 120 BDL 120 1600.5 5120 NI 
TIL020 M 51 2 7 BDL 7 454.4 10240 NI 
Non-KS 
(KSHV+, 
HIV-1-) 
3067 F 60 NA NA NA NA 224.6 5120 NI 
Non-KS 
(KSHV+, 
HIV-1+) 
21598 F 45 NA 36 NI NI 197.1 2560 NI 
594 F 33 NA 18 NI 12 175.4 2560 NI 
649 F 25 NA 6 NI 4 126.1 640 NI 
‘+’ denotes KSHV virions present in plasma, and ‘−’ denotes KSHV virions not present in plasma. 
Abbreviations: KSHV, Kaposi’s sarcoma-associated herpesvirus; KS, Kaposi sarcoma; HIV-1, human 
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immunodeficiency virus type 1; ARV, Antiretrovirals; IFA, immunofluorescence assay; NA, not 
applicable; NI, no information; BDL, below detection limit. IFA numbers represent total anti-KSHV 
antibody titer (reciprocal endpoint plasma dilution); 1/IC50 numbers represent the dilution of 
plasma that has a 50% neutralizing activity. Green denotes Endemic KS cases. Red denotes Epidemic 
KS cases. Blue denotes Non-KS controls without or with HIV-1 infection. 
3.2. KSHV Envelope Glycoprotein Expression in 293T Cells 
Plasmids encoding KSHV envelope glycoproteins gB, ORF28, ORF68, gH, gL, gM, gN and 
gpK8.1 were generated by cloning the full-length sequence of each gene into the pcDNA3.1 
mammalian expression vector (Figure 1A). To facilitate the detection of these glycoproteins, the 
sequence for the 3xFLAG epitope was fused to the carboxyl-terminus of each glycoprotein construct, 
the expression of which was evaluated after transfection of 293T cells. At 72 hours post-transfection, 
high expression levels of all KSHV glycoproteins were detected in the whole-cell lysates of their 
respective transfected cells using immunoblotting against the 3xFLAG tag, demonstrating that all 
the KSHV glycoprotein-expressing constructs are functional (Figure 1B). However, since the input 
plasmids transfected into the cells was based on total DNA amount, rather than equal copy number, 
there is some variation in expression among different glycoproteins. For most of the KSHV 
glycoproteins, their corresponding bands, as reported by other groups, were detected by 
immunoblot in the total cell lysates [17,20,22,35]. However, the molecular weight of the gM protein 
in our study is higher than its theoretical size of 45 kDa. To determine the cause of this unexpectedly 
high molecular weight of gM protein, the gM expression plasmid was sequenced, but no mutations 
were found. Furthermore, post-translational glycosylation was also ruled out with Endo H 
treatment, where the molecular weight of gM remained unchanged after treatment (data not 
shown). Further investigation on how post-translational modifications such as phosphorylation 
affected the size of gM protein will be warranted. 
 
Figure 1. Kaposi’s sarcoma-associated herpesvirus (KSHV) envelope glycoprotein constructs and 
their expression in 293T cells by immunoblot. (A) Schematic representation of pcDNA3.1 
mammalian expression vector encoding KSHV glycoproteins fused with 3xFLAG at the C-terminus 
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of each glycoprotein (not drawn to scale). (B) KSHV glycoproteins expression was demonstrated in 
the whole-cell lyses of transfected 293T cells by immunoblot against the 3xFLAG tag. 
To further confirm the expression and transfection efficiency for each glycoprotein and to 
demonstrate that the majority of the transfected cells indeed express the glycoproteins, 
immunohistochemistry (IHC) staining against the 3xFLAG tag was performed on the transfected cell 
cultures in situ at 72 hours post-transfection. Since previous studies suggested that gH and gL form a 
noncovalent complex that is necessary for efficient transport of gL to the cell surface, cotransfection 
of gH/gL was also investigated [36]. Likewise, due to the previous reports that gN is required for 
functional processing of gM and together they form heterodimer, co-infection of gN/gM was 
included as well [37]. In agreement with the immunoblot results, the IHC demonstrated intense 
brown-color-stained cells, indicating high protein expression for all the KSHV glycoproteins in 
transfected cells (Figure 2A). Importantly, the majority of the cells in the transfected culture 
expressed their respective KSHV glycoprotein, demonstrating high transfection efficiency of each 
KSHV glycoprotein-encoding plasmid. Nontransfected and empty-vector-transfected 293T controls 
produced no evident chromagen deposition. 
 
Figure 2. KSHV envelope glycoproteins expression in 293T cells by immunohistochemistry IHC and 
immunofluorescence assay (IFA). (A) KSHV glycoproteins expression was confirmed in 293T cells at 
72 hours post-transfection by IHC against the 3xFLAG tag. Positive cells are stained brown. (B) The 
cell surface expression of KSHV glycoproteins was confirmed by IFA on nonpermeabilized 293T cells 
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at 72 hours post-transfection with pooled plasma from all study participants. Positive cells are 
indicated by white arrows. Pictures were taken at 20X magnification. 
Additionally, to demonstrate that KSHV glycoproteins are indeed expressed on the transfected 
cell surface, IFA was performed on nonpermeabilized 293T cells at 72 hours post-transfection using 
a pooled plasma from all the study participants (n = 25) as the primary detection antibody. The cell 
surface expression of all the KSHV glycoproteins was confirmed by the presence of green-colored 
cells (Figure 2B). Among the glycoproteins, the signal for ORF28, ORF68, gL alone and gM alone 
were relatively weak, which could be due to low levels of antibodies against these proteins in the 
pooled plasma. However, the combinations of gH/gL or gM/gN have relatively stronger green signal 
in comparison to respective single-plasmid-transfected cells, indicating that interaction between 
gH/gL or gM/gN potentiates recognition of these complexes by KSHV-infected plasma [36,37]. No 
signal was detected in the nontransfected and empty-vector-transfected 293T cells. 
3.3. Antigenic Determinant of KSHV-Specific nAbs in the Plasma of KSHV-Infected Individuals 
To determine which KSHV glycoprotein(s) are the target for KSHV-specific nAbs in the plasma 
of the non-KS asymptomatic individuals and KS patients, 293T cells expressing various KSHV 
glycoproteins were incubated with their plasma (n = 25) to adsorb nAbs against specific 
glycoproteins. The residual neutralizing capability of the depleted plasma was then quantified in a 
flow-cytometry-based neutralization assay. If nAbs against a specific KSHV glycoprotein were 
prevalent in a plasma, depletion by the 293T cells expressing that particular glycoprotein would 
result in a reduction in the ability of the depleted plasma to neutralize. These neutralization titers 
were then normalized with the percent neutralization of the identical plasma absorbed with empty 
vector-transfected cells and reflected as a relative percent nAbs absorbed. 
Among the 15 EpKS cases, 80% of the patients’ plasma contained nAbs that could recognize 
eight out of 10 variations of the KSHV glycoproteins examined (Figure 3A). Only patients 21001, 
21052 and TIL020 had nAbs that recognized less than 50% of the KSHV glycoproteins. Despite this 
breadth of KSHV glycoprotein recognition, the magnitude of neutralization attributable to each 
glycoprotein varied widely among individuals. For instance, there was a higher level of 
ORF28-specific nAbs in patient 21017 as compared to patient 3122. Similar patterns of nAbs breadth 
and magnitude were detected in the six EnKS and four non-KS cases (Figure 3B,C, respectively). 
Interestingly, among the entire cohort, only the gH/gL complex was consistently recognized by the 
majority of patients nAbs at high levels. In comparison to other KSHV glycoproteins, the near 80% 
response to gH/gL was significantly higher than that against all other glycoproteins or complexes 
(p-values ranged p < 0.001 to p < 0.0001) (Figure 4). Additionally, there is no correlation between the 
gH/gL-specific nAbs and the total anti-KSHV and total KSHV-specific nAbs responses, despite the 
fact that 80% of our study participants had demonstrated high level of nAbs against the gH/gL 
complex (Supplementary Figure S3A,B). Furthermore, no correlation was found between the nAbs 
responses against gH/gL complex and age, sex or symptomatic KS duration in the cohort 
(Supplementary Figure S3C–E). 
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Figure 3. Antigenic determinant of KSHV-specific neutralizing antibodies (nAbs) in the plasma of 
KSHV-infected individuals. Heat-inactivated plasma of the study participants was absorbed with 
KSHV glycoproteins-expressing 293T cells, and neutralization assays were carried out as described 
in material and methods. The relative percentage of nAbs absorbed is shown for (A) epidemic KS 
(EpKS) cases, (B) endemic KS (EnKS) cases and (C) non-KS (asymptomatic KSHV-infected ) cases. 
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Figure 4. Comparison of nAbs responses among various KSHV envelope glycoproteins. The gH/gL 
complex-specific nAbs response was compared with other KSHV glycoproteins among all the 
participants using the Mann–Whitney test (*** p < 0.001, **** p < 0.0001). 
3.4. Similar nAbs Responses towards KSHV Glycoproteins Regardless of KS Status 
Our lab has previously shown that the magnitude of total KSHV nAbs responses are 
indistinguishable between EpKS and EnKS but are significantly higher in KS patients than non-KS 
individuals [34]. To determine if these observations extend to the KSHV glycoprotein-specific nAbs 
responses, the relative percent of nAbs depleted by each KSHV glycoprotein was compared between 
the EpKS, EnKS and non-KS groups. Unlike the total KSHV nAbs responses, the KSHV 
glycoprotein-specific nAbs responses were not statistically different between KS and non-KS groups 
(Figure 5). Thus, although the development of KS increased the magnitude of total nAbs in 
symptomatic patients, it had no detectable effect on the breadth and glycoprotein specificity in that 
increased response. Additionally, co-infection with HIV-1 seems to have no significant effect on the 
nAbs responses. 
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Figure 5. Comparison of nAbs responses to each KSHV glycoprotein in the EnKS, EpKS and non-KS 
groups. The nAbs responses against each KSHV glycoproteins were compared between the EnKS, 
EpKS and non-KS individuals using the Mann–Whitney test. 
4. Discussion 
Neutralizing antibodies are a powerful defense against many viral infections in animals and 
humans [38]. The nAbs against infections caused by viruses, such as influenza and flavivirus, have 
been shown to prevent viral infection; thus, it suggests that a similar approach may also be feasible 
in preventing KSHV infection [39–42]. Although KSHV-specific nAbs did not prevent the 
development of KS, whether the presence of these nAbs prior to exposure to KSHV would prevent 
infection is still unclear [13]. 
Since KSHV envelope glycoproteins are incorporated into the viral surface and are critical for 
viral entry into permissive cells, they are the candidate antigens for eliciting nAbs through 
vaccination. In recent years, several studies have shown that immunizing mice or rabbits with 
Newcastle disease virus-like particles (VLP) expressing KSHV gpK8.1, gB and gH/gL, either alone or 
together, can elicit nAbs responses against KSHV [16,17]. However, whether these 
glycoprotein-targeted responses are consistent with those in KSHV-infected individuals with strong 
neutralizing responses has not yet been investigated. Addressing this question could provide 
insights for the design of prophylactic vaccines against KSHV. 
Our study is the first to define the specificities of nAbs responses within KSHV-infected 
individuals’ plasma against KSHV envelope glycoproteins. In addition, ours is the first study to 
investigate whether differentials in magnitude or breadth of nAbs specificities exist between EnKS, 
EpKS and non-KS individuals. To ensure that our results were not affected by the different KSHV 
glycoproteins expression, an equal copy number of each glycoprotein-encoding plasmid was 
transfected into equal number of cells, which was then used for the adsorption of nAbs from sample 
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plasma with optimized number of cells, time and incubation temperature (Supplementary Figure 
S1B,C). A good example to support our conclusion that the protein expression did not affect the 
adsorption result is gpK8.1, which were highly expressed in transfected cells based on the 
immunoblot, IHC and IFA data, but only a small amount of nAbs was adsorbed by it. Using our 
optimized assays, we found that the neutralizing component of plasma in a majority of the study 
participants targeted multiple KSHV envelope glycoproteins. Although these glycoproteins can 
elicit nAbs in infected individuals, the magnitude of the neutralization response varies widely 
among individuals with some glycoproteins eliciting much stronger response in one individual than 
another. This strongly indicates that nAbs responses elicited by any KSHV envelope glycoprotein 
are highly individualized. 
Among all the KSHV glycoproteins, only the gH/gL complex elicited nAbs responses that are 
consistent and comparable among most individuals. Eighty percent of study participants showed 
high levels of nAbs against the gH/gL complex. Given this consistently strong nAbs reaction against 
gH/gL from different individuals, we speculate that gH and gL may undergo conformational 
changes when complexed, which then expose yet-to-be-determined epitopes that are highly 
immunogenic, resulting in its high recognition by over 80% of the infected individuals. Interestingly, 
several individuals, such as patients 21062 and TIL002, had nAbs that recognized both gH/gL and 
gM/gN, while other individuals also have similar nAbs among different glycoproteins. One possible 
explanation for this observation could be that some nAbs are targeting the carbohydrate moieties, 
which might be common among different KSHV envelope glycoproteins. For example, studies have 
shown that KSHV gB is associated with high levels of mannose which could be targeted by 
KSHV-specific nAbs, but only in some individuals [43]. Another possibility is the presence of nAbs 
that recognize certain yet-to-be-determined conformational epitopes that may only be exposed when 
the KSHV glycoproteins interact with one another. This is feasible if these glycoproteins are in close 
proximity with one another on the virion surface. Unfortunately, there is very little information on 
the KSHV glycoprotein homo- or hetero-oligomeric structures and certainly none for those on the 
KSHV virion; therefore, more studies will be needed to support our observations. 
Although our previous finding indicated that the total KSHV nAbs responses are similar in 
EnKS and EpKS, and that these responses are higher compared to asymptomatic individuals, we 
found no evidence for such differences in terms of nAbs specificities against different KSHV 
glycoproteins [34]. Thus, it would appear that the diversity of KSHV glycoproteins-specific nAbs 
responses is independent of KS disease progression, whereas the magnitude of the total KSHV nAbs 
response increases with disease progression, and both are independent of HIV-1 co-infection. We 
also did not find any correlation between KSHV glycoprotein-specific nAbs responses and the 
presence of KSHV virions in the plasma at the time of sampling. This may indicate that there is a 
tissue reservoir that is providing the necessary antigens to elicit humoral responses or that these are 
anamnestic responses from previous episodes of higher plasma viral load. 
In summary, our data suggest that the KSHV glycoproteins gH/gL complex is the most 
prominent target for elicitation of nAbs in KSHV-infected individuals regardless of KS status. Thus, 
the KSHV glycoproteins gH/gL complex should be considered as a potential antigen in future KSHV 
prophylactic vaccine design. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Titration of 
rKSHV.219, optimization conditions for absorption of plasma with KHSV glycoprotein expressing 293T cells. 
(A) rKSHV.219 titration in 293T cells. 293T cells were seeded at a density of 2.5 × 106 in triplicates into a 96-well 
plate. The cells were then infected with either 10, 20, 30, 40, 60 or 80 µl of concentrated virus in a total volume of 
200 µL for 72 h at 37 °C. Infected cells (GFP+ cells) were quantified using FACS by acquiring a total of 10000 
events. (B) Optimization of binding temperature during absorption of nAbs with gH/gL complex expressing 
293T cells. (C) Optimization of the number of gH/gL complex expressing 293T cells during absorption with 
nAbs., Figure S2: Total KSHV-specific nAbs of the study participants. Neutralization assays were conducted by 
incubating rKSHV.219 with heat-inactivated plasma at 1:50 dilutions. The level of neutralization was 
determined after 72 hours using flow cytometry to quantify the number of GFP+ cells acquiring a total of 10000 
events. Figure S3: Comparison of the magnitude of nAb responses to KSHV gH/gL complex with; total 
anti-KSHV antibodies and with total KSHV-specific nAb responses, age, sex and symptomatic KS duration. The 
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correlation between the extent of nAb absorbed by gH/gL and (A) total anti-KSHV and (B) nAb responses, (C) 
age, (D) sex and (E) symptomatic KS duration was performed using nonparametric Spearman correlation 
analysis (ns P >0.05). 
Author Contributions: Y.M. performed all experiments and compiled the manuscript. S.J.L and T.T. performed 
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study. All authors provided critical input to the manuscript and approved the final version. 
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